CNS Pharmaceuticals Transfers Orphan Drug Designation for TPI 287 with Positive Results
CNS Pharmaceuticals announces successful transfer of Orphan Drug Designation for TPI 287, showing promising results in Phase 1 trial. Learn more about the company's advancements in brain cancer treatment.
This news matters as it signifies a significant milestone for CNS Pharmaceuticals in advancing treatment options for brain and CNS cancers. The successful transfer of Orphan Drug Designation for TPI 287 demonstrates the potential for improved therapies in glioblastoma and other neurodegenerative diseases.